Herpes zoster virus vaccine

Geriatrics

Volumn 63, Issue 10, 2008, Pages 6-9

  Woolery, William Alan ^a  

^a MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Herpes zoster virus; Varicella zoster virus

Indexed keywords

ACICLOVIR; CHICKENPOX VACCINE; INFLUENZA VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE; TETANUS TOXOID; VALACICLOVIR; VARICELLA ZOSTER VACCINE;

ARTICLE; ASTHMA; CHICKENPOX; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG EFFICACY; HEADACHE; HERPES ZOSTER; HUMAN; INFLUENZA; INJECTION SITE REACTION; NONHUMAN; PAIN; POSTHERPETIC NEURALGIA; RHEUMATIC POLYMYALGIA; SINGLE DRUG DOSE; STREPTOCOCCUS INFECTION; SWELLING; TETANUS; UNSPECIFIED SIDE EFFECT; VARICELLA ZOSTER VIRUS; AGE; AGED; IMMUNIZATION; REVIEW; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; IMMUNIZATION, SECONDARY; TREATMENT OUTCOME;

EID: 54049083010     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Schmader K. Herpes zoster and postherpetic neuralgia in older adults. Clin Geriatr Med. 2007;23(3):615-632.
2. DeYoung GR, Baty PJ. Herpes zoster vaccine (Zostavax) for the Prevention of Shingles. Amer Fam Phys. 2007;75(12):1843-1844.
3. Holcomb K, Weinberg JM. A novel vaccine (Zostavax) to prevent herpes zoster and post herpetic neuralgia. J Drugs Dermatol. 2006;5(9):863-866.
4. Merck. Zostavax Package Insert. 2006.
5. Jung BF, Johnson RW, Griffin DR, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology. 2004;62(9):1545-51.
6. Oyman MN, Levin MJ, Johnson GR, et al. Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-2284.
7. Cunningham AC, Brewer J, Dwyer DE, et al. The prevention and management of herpes zoster. Med J Aust. 2008;188(3):171-6.
8. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007;356(13);1338-1343.
9. Holodniy M. Prevention of shingles by varicella zoster virus vaccination. Expert Rev Vaccines. 2006;5(4):431-443.
10. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30; Erratum in: MMWR Recomm Rep. 2008;57(28):779.
11. Tyring SK, Diaz-Mitoma F, Padget LG, et al. Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of age. Vaccine. 2007;25(10):1877-1883.
12. Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis. 2007;44(10):1280-1288.
13. Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med. 2006:245(5):317-325.
14. Sutradnar SC, Wang WWB, Schlienger K, et al. Comparison of immunogenicity and safety of Zostavax in adults 50 to 59 years old and those > 60 years old. [Abstract s27]. 10th Annual Conference on Vaccine Research, 2007, April 30-May 2, Baltimore, MD.
15. Kerzner B, Murray AV, Cheng E, et al. Safety and immunogenicity profile of the concomitant administration of Zostavax and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatir Soc. 2007;55(10):1499-1507.
16. Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008;197(6):825-835.